Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 28, 2015

Primary Completion Date

May 11, 2018

Study Completion Date

May 11, 2018

Conditions
Brain Mapping
Interventions
OTHER

Brain connectivity and physiology

Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.

OTHER

Brain Wave

ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

NCT02311374 - Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness | Biotech Hunter | Biotech Hunter